Shanghai Ucombe Pharmaceutical Technology Co., Ltd. is a high-tech enterprise specializing in the research, development, production and sales of plant-based pharmaceutical excipients and innovative preparations of traditional Chinese medicine. With the mission of “promoting drug safety and safeguarding human health”, the company is committed to becoming a global pioneer in plant-based capsule manufacturing. Relying on the continuous technological innovation and intelligent manufacturing capabilities, Tsuenjikang continues to make breakthroughs in the fields of plant-based materials and pharmaceutical production automation, and actively leads the traditional pharmaceutical industry to transform into a high-quality, green and sustainable direction.

  Our core product, plant-based hollow capsules, is made from plant extracts (e.g. hydroxypropylmethylcellulose), which has the advantages of naturalness, safety, low water content, not easily brittle, good disintegration, and strong drug compatibility, making it an ideal alternative to gelatin capsules. With superior performance and higher safety, plant-based capsules are becoming an important development direction for the global pharmaceutical industry. Ucombe has successfully completed the pilot test of second-generation plant capsules and realized the large-scale production of potato modified starch and seaweed polysaccharide as raw materials, which ensures the quality and reduces the cost by about 40%, and the product qualification rate is as high as 99.9%. The relevant projects have a number of domestic and international patents covering formulations, processes, equipment and environmental standards, and all the products have been exported and passed the national drug certification, in line with international pharmaceutical standards.

  In promoting the modernization of traditional Chinese medicine, Ucombe takes “Oral Dissolving Film” as the core, integrating the concept of traditional Chinese medicine with modern drug technology, providing children, the elderly and people with swallowing difficulties with a more convenient and efficient way of taking medication. The preparation can have a rapid onset of action and improve the bioavailability of the drug, which is an important breakthrough in the internationalization of traditional Chinese medicine. Tsuenjikang also leverages artificial intelligence technology to continuously optimize formulation design and therapeutic effects, expanding the global application scenarios of Chinese medicine preparations.

  Currently, the company's R&D and operation headquarters is located in Shanghai, and it has built a production demonstration base of 4 billion capsules in North China, with all of its products sold in overseas markets. The production clusters in Northeast and Northwest China with planned capacity of 40 billion capsules are under active construction and are expected to be put into production by the end of 2025. Central China, East China and South China clusters will soon land. The company plans to realize the full completion of the six industrial clusters by 2028, and increase the total annual production capacity to 200 billion capsules, so as to build a global advanced industrial platform for plant-based materials.

  Looking ahead, Ucombe will continue to increase its investment in research and development, focusing on the continuous upgrading of plant-based materials, intelligent manufacturing and new formulation technologies. Through technological innovation and globalization, the company will provide global consumers with better quality, environmentally friendly and safer pharmaceutical and health products, and help build a green and sustainable global pharmaceutical industry ecosystem. As an important promoter of the modernization of Chinese traditional medicine in China, Ucombe is moving towards the global market at a determined pace, contributing to the cause of human health.